AE-free PFS benefit with first-line ibrutinib plus venetoclax for CLL: 64-month follow-up of GLOW
Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, comments on the long-term results of the Phase III GLOW study (NCT03462719), a trial evaluating first-line ibrutinib plus venetoclax versus chlorambucil plus obinutuzumab in elderly or comorbid patients with chronic lymphocytic leukemia (CLL). Dr Niemann highlights that the ibrutinib plus venetoclax combination demonstrates a significant adverse event (AE)-free progression-free survival (PFS) benefit, with patients achieving over 20 months of toxicity-free PFS, compared to less than half a year with chlorambucil plus obinutuzumab. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
